Table 1.
EC50 and CC50 values for the effect of itraconazole, 17‐OH itraconazole and remdesivir on SARS‐CoV‐2 replication and the viability of Caco‐2 cells
| Assessment | Itraconazole | 17‐OH itraconazole | Remdesivir |
|---|---|---|---|
| Antiviral activity | |||
| EC50 by visual scoring of inhibition of CPE, µM | 1.5 | 1.2 | 0.3 |
| EC50 by MTT assay, µM | 2.3 | 3.6 | 0.4 |
| Cell viability | |||
| CC50, µM | >50 | >100 | >100 |
Abbreviations: CC50, cytotoxic concentration of the compound that reduced cell viability to 50%; CPE, cytopathogenic effect; EC50, concentration of the compound that inhibited 50% of the infection; MTT, 3‐(4,5‐dimethylthiazol‐2‐yl)−2,5‐diphenyltetrazolium bromide; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2.